Solventum Research and Development Expenses 2023-2024 | SOLV
Solventum annual/quarterly research and development expenses history and growth rate from 2023 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
- Solventum research and development expenses for the quarter ending December 31, 2024 were $199M, a 4.74% increase year-over-year.
- Solventum research and development expenses for the twelve months ending December 31, 2024 were $775M, a 2.24% increase year-over-year.
- Solventum annual research and development expenses for 2024 were $0.775B, a 2.24% increase from 2023.
- Solventum annual research and development expenses for 2023 were $0.758B, a 1.17% decline from 2022.
- Solventum annual research and development expenses for 2022 were $0.767B, a 0% decline from .
| Solventum Annual Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2024 | $775 |
| 2023 | $758 |
| 2022 | $767 |
| Solventum Quarterly Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2024-12-31 | $199 |
| 2024-09-30 | $189 |
| 2024-06-30 | $192 |
| 2024-03-31 | $195 |
| 2023-12-31 | $190 |
| 2023-09-30 | $180 |
| 2023-06-30 | $193 |
| 2023-03-31 | $195 |
| 2022-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $12.620B | $8.254B |
| Solventum is an independent healthcare company. Its business segment includes Medical Surgical, Dental Solutions, Health Information Systems and Purification and Filtration. Solventum is based in ST. PAUL, Minn. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $136.657B | 25.63 |
| Elevance Health (ELV) | United States | $88.114B | 11.37 |
| CVS Health (CVS) | United States | $76.496B | 9.51 |
| Cencora (COR) | United States | $55.428B | 19.28 |
| DiDi Global (DIDIY) | China | $22.215B | 33.71 |
| Natera (NTRA) | United States | $20.400B | 0.00 |
| BioMerieux (BMXMF) | France | $15.355B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $12.158B | 0.00 |
| CochLear (CHEOY) | Australia | $11.298B | 0.00 |
| Doximity (DOCS) | United States | $10.912B | 50.83 |
| Revvity (RVTY) | United States | $10.655B | 18.34 |
| ICON (ICLR) | Ireland | $10.552B | 9.81 |
| Viatris (VTRS) | United States | $10.317B | 3.54 |
| Avantor (AVTR) | United States | $8.750B | 12.71 |
| Medpace Holdings (MEDP) | United States | $8.519B | 22.63 |
| HealthEquity (HQY) | United States | $8.446B | 41.55 |
| Sonic Healthcare (SKHHY) | Australia | $8.201B | 0.00 |
| Charles River Laboratories (CRL) | United States | $6.822B | 13.37 |
| Amplifon S.p.A (AMFPF) | Italy | $4.966B | 26.21 |
| BrightSpring Health Services (BTSG) | United States | $4.185B | 38.74 |
| Bausch + Lomb (BLCO) | Canada | $4.171B | 24.58 |
| Sotera Health (SHC) | United States | $3.616B | 20.55 |
| Surgery Partners (SGRY) | United States | $3.029B | 39.39 |
| Alignment Healthcare (ALHC) | United States | $2.948B | 0.00 |
| Concentras Parent (CON) | United States | $2.925B | 16.90 |
| Organon (OGN) | United States | $2.280B | 2.42 |
| Ardent Health Partners (ARDT) | United States | $2.179B | 9.29 |
| Progyny (PGNY) | United States | $1.882B | 41.42 |
| Premier (PINC) | United States | $1.877B | 14.24 |
| GeneDx Holdings (WGS) | United States | $1.815B | 69.90 |
| PACS (PACS) | United States | $1.625B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.432B | 28.64 |
| Pediatrix Medical (MD) | United States | $1.278B | 9.73 |
| Teladoc Health (TDOC) | United States | $1.272B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.059B | 0.00 | |
| Agilon Health (AGL) | United States | $1.056B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $0.998B | 0.00 |
| Nutex Health (NUTX) | United States | $0.967B | 14.61 |
| CareDx (CDNA) | United States | $0.896B | 14.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.857B | 8.02 |
| QDM (QDMI) | Hong Kong, SAR China | $0.729B | 0.00 |
| Embecta (EMBC) | United States | $0.681B | 4.59 |
| InnovAge Holding (INNV) | United States | $0.570B | 0.00 |
| Enhabit (EHAB) | United States | $0.545B | 44.83 |
| Auna S.A (AUNA) | Luxembourg | $0.514B | 13.63 |
| Sonida Senior Living (SNDA) | United States | $0.493B | 0.00 |
| LifeMD (LFMD) | United States | $0.439B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.367B | 0.00 |
| SBC Medicals (SBC) | United States | $0.361B | 0.00 |
| Oncology Institute (TOI) | United States | $0.230B | 0.00 |
| Beauty Health (SKIN) | United States | $0.217B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.204B | 0.00 |
| DocGo (DCGO) | United States | $0.143B | 23.33 |
| Sera Prognostics (SERA) | United States | $0.090B | 0.00 |
| KindlyMD (KDLY) | United States | $0.083B | 0.00 |
| So-Young (SY) | China | $0.083B | 0.00 |
| OncoCyte (OCX) | United States | $0.080B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.071B | 0.00 |
| NeueHealth (NEUE) | United States | $0.062B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.057B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.049B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.035B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.033B | 0.00 |
| Biodesix (BDSX) | United States | $0.032B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.013B | 0.00 |
| ModivCare (MODV) | United States | $0.013B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.010B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.009B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |